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Background and purpose: In previous experiments an enhanced anti-proliterative effect of the EGFR/ErbB tyrosine
kinase inhibitor (TKI) BIBW 2992 with single dose irradiation was observed in FaDu tumour xenografts. Aim of the
present experiment was to determine if this effect can also be seen in combination with a fractionated radiotherapy.
Secondly we investigate the efficacy of BIBW 2992 on local tumour control for UT-SCC-15.
Material and methods: Tumour pieces of FaDu, UT-SCC-14, A431, UT-SCC-15 (squamous cell carcinomas) and A7
(glioma) tumour models were transplanted onto the right hind leg of NMRI (nu/nu) nude mice. For evaluation of
tumour growth mice were either treated daily orally with BIBW 2992 (30 mg/kg body weight), or carrier up to a
final tumour size of 15 mm or with a fractionated radiotherapy (15f/15d, 30 Gy) with simultaneous application of
BIBW 2992 or carrier. For local tumour control UT-SCC-15 tumours were treated with a fractionated radiotherapy
(30f/6weeks) or received 30f/6 weeks in combination with daily orally BIBW 2992 (22.5 mg/kg b.w.) during RT.
Results: A significant effect on tumour growth time was observed in all tumour models for BIBW 2992
application alone. However, substantial intertumoural heterogeneity could be seen. In the UT-SCC-14, UT-SCC-15
and A431 tumour models a total regression of the tumours and no recurrence during treatment time (73 days)
were determined where as for the A7 tumour only a slight effect was noticeable. For the combined treatment of
fractionated radiotherapy (15f/15d) and BIBW 2992 administration a significant effect on tumour growth time was seen
compared to irradiation alone for A7, UT-SCC-15 and A431 (ER 1.2 – 3.7), this advantage could not be demonstrated for
FaDu and UT-SCC-14. However, the local tumour control was not altered for the UT-SCC-15 tumour model when
adding BIBW 2992 to fractionated irradiation (30f/6weeks).
Conclusion: A heterogeneous effect on tumour growth time of BIBW 2992 alone as well as in combination with
fractionated irradiation could be demonstrated for all tumour models. However, the significant effect on tumour
growth time did not translate into an improvement of local tumour control for the UT-SCC-15 tumour model.
Keywords: Combined treatment, Molecular targeting, EGFR/ErbB-inhibition, Fractionated irradiation, Local tumour
control, BIBW 2992* Correspondence: kristin.gurtner@uniklinikum-dresden.de
1Department of Radiation Oncology, UniversityHospital C.G. Carus,
Fetscherstr. 74, 01307 Dresden, Germany
2OncoRay – National Centerfor Radiation Research in Oncology, Medical
Faculty and University Hospital Carl Gustav Carus, TechnischeUniversität and
Helmholtz-Zentrum Dresden –Rossendorf, Dresden, Germany
Full list of author information is available at the end of the article
© 2014 Gurtner et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Gurtner et al. Radiation Oncology 2014, 9:261 Page 2 of 9
http://www.ro-journal.com/content/9/1/261Introduction
Overexpression of the epidermal growth factor receptor
(EGFR) on tumour cells has been shown to increase
chemo- and radioresistance and therefore is associated
with a poor outcome [1-3]. Inhibition of the EGFR in
combination with radiotherapy has become a promising
strategy to overcome this resistance. While anti-EGFR
antibodies like cetuximab have the potential to prolong
tumour growth and improve local tumour control when
applied simultaneously to irradiation [4-10], for tyrosine
kinase inhibitors (TKI), e.g. Erlotinib, the prolongation
of tumour growth time did not translate into improved
curative effects [1,8,11]. Clinical evaluation of EGFR-TK
inhibition in combination with chemo- or radiotherapy
revealed also heterogeneous effects [1,12]. One reason
for the rather minor effects of TKI on local tumour
control could be that through heterodimerisation with
other receptors of the EGFR-family, e.g. ErbB2, signal-
transduction is still possible and therefore exclusively
blocking the EGFR-TK is not sufficient [13-15]. Targeting
more than one receptor of the EGFR-family might there-
fore show a therapeutic benefit.
BIBW 2992 is an irreversible ErbB-family (EGFR/ErbB2/
ErbB4) inhibitor, which in previous experiments demon-
strated a significant prolongation of tumour growth
time in a combined setting with single dose irradiation
in FaDu tumour xenografts. In vitro but not in vivo a
radiosensitizing effect could be shown for this tumour
model. The antiproliferative effects are in line with a
clear G0/G1 arrest of the tumour cells [16]. Based on
these findings, the aim of the current study was to
investigate the effect of BIBW 2992 with or without frac-
tionated irradiation on tumour growth in five different
human tumour xenografts (A7, A431, FaDu, UT-SCC-14
and UT-SCC-15). Consecutively, after these first experi-
ments a local tumour control experiment was performed




7 to14-week-old male and female NMRI (nu/nu) mice
from the specific pathogen-free animal breeding facility
of the Experimental Center of the Medical Faculty Carl
Gustav Carus, Technische Universität Dresden were used
for the experiments. The facility veterinarians checked the
microbiological status of the animals regularly. The exper-
iments and animal facilities were approved according to
the German animal welfare regulations. Water ad libitum
and a commercial laboratory animal diet were provided
for the animals. A constant temperature of 26°C, day-
light in addition to a 12 h light–12h dark electric cycle
(light-on time 07.00 a.m.) and a relative humidity of 50-60%
were supplied within the animal room. A whole-bodyirradiation 2 – 5 days before tumour transplantation
with 4 Gy using 200 kV X-rays (0.5 mm Cu) at a dose
rate of about 1 Gy/min was given for further immuno-
suppression of the animals.
Four established human squamous cell carcinoma
lines (FaDu, UT-SCC-14, UT-SCC-15, A431) and a gli-
oma cell line (A7) were used in this study. UT-SCC-14
and UT-SCC-15 were established by Prof. Reidar
Grenman (University of Turku, Finland). UT-SCC-14
[17,18] was derived from a squamous cell carcinoma of the
tongue, UT-SCC-15 [17] is a tumour cell line originating of
a recurrent tumour of the tongue. FaDu is an undif-
ferentiated tumour of the hypopharynx [6,17,19-21],
originally obtained from the American Type Culture
Collection (ATCC) that differs from the original tumour
by an additional loss of heterozygosity in the p53 gene
(TP53) [22]. A431 is a squamous cell carcinoma of the
female genitales (DSMZ, German Collection of Micro-
organisms and Cell Cultures, Braunschweig, Germany)
and A7 is a glioblastoma cell line (Gray Cancer Institute,
Mount VernonHospital, Northwood, Middlesex, Great
Britain). A cryostock of tumour pieces of all tumour
models is kept in Dresden. Out of the cyrostock, gener-
ated tumours were passaged in nude mice over 2 gener-
ations. The origin of the tumours was validated during
passaging by histological examinations, short tandem
repeats analysis (microsatellites), and lactate dehydro-
genase isoenzyme pattern. Additional histological exam-
inations, evaluations of the volume doubling time and
of the lactate dehydrogenase isoenzyme pattern were
carried out in parallel to the experiments to ensure
constancy of the models and exclude murinization. No
or very little residual immune response in nude mice
was shown for 4 of the 5 cell lines in previously reported
studies [17,23-26]. For A431 tumours local control ex-
periments with and without whole body irradiation
were performed revealing no immune response reaction
against this tumour line by nude mice. The TCD50 for
single dose irradiation under clamp conditions with
whole body irradiation was 58.6 Gy [95% CI: 60;174]
and without whole body irradiation 67.8Gy [95% CI:
51;277] (p = 0.577).
In the experiments, tumour pieces of 1–2 mm diameter
were transplanted subcutaneously into the right hind
leg of anesthetised (16 mg/kg body weight (b.w.) xylazine
[intraperitoneal, i.p.] and 120 mg/kg b.w. ketamine [i.p.])
animals. All procedures for tumour transplantation have
been described previously in detail [8,26-28].
Animal welfare approval number: 24D-9168.11-1/
2006-20.
Administration of BIBW 2992
BIBW2992, a second generation tyrosine kinase inhibitor
of the epidermal growth factor receptor (EGFR) family
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the EGFR and ErbB2 and ErbB4-receptor [29,30]. Its
effectiveness in vitro and in vivo has been shown to be
greater than that of the first generation TKIs (e.g. erlotinib)
[30] and resistance to first generation EGFR inhibitors
could be overcome in certain cell lines by BIBW 2992 [29].
BIBW 2992 was kindly supplied by Boehringer Ingelheim
RCV, Vienna Austria.
For evaluation of the drug effect alone, carrier or
BIBW 2992 was administered daily orally at a concentra-
tion of 30 mg/kg b. w. up to the final size of the tumour
(one diameter reaching 15 mm). Within the combined
treatment, carrier or BIBW 2992 were only given simul-
taneously during fractionated irradiation using the same
application and concentration schedule mentioned above,
with a 4 hour interval before each irradiation fraction.
For the local control experiment a lower BIBW 2992
concentration (22.5 mg/kg b.w.) was administered due
to observed toxicity within the previous experiments.
Local tumour irradiation
Local tumour irradiation was carried out under ambient
conditions to air-breathing animals without anaesthesia
(200 kV X-rays, 0.5 mm Cu, single beam, dose rate ~1
Gy/min, source to skin distance 42 cm). Specially de-
signed jigs were able to hold 5 animals for simultaneous
irradiation. The tumour-bearing leg was held positionedA
B
C
Figure 1 Experimental design. A) Application of either carrier or BIBW 29
(15f; total dose 30 Gy) in combination with carrier or BIBW 2992 during irra
between 20 and 120 Gy) in combination with carrier or BIBW 2992 duringin the irradiation field while mice were immobilized in a
plastic tube which was fixed on a lucite plate by a foot-
holder distal to the tumour.Experimental design
The first experiment was divided into 2 arms (Figure 1): in
arm (A) animals were treated with either carrier or BIBW
2992 orally daily up to the final size of the tumour (14–16
animals per group). In the second arm (B) tumours were
additionally irradiated with 15 fractions applying one frac-
tion per day (14–16 animals per group). Carrier or BIBW
2992 were given 4 hours before each irradiation fraction
without continuation after the end of irradiation.
For the local tumour control experiment (C), the
UT-SCC-15 tumour model was selected as the best
responding model regarding tumour growth time (Figure 2).
UT-SCC-15 tumours were irradiated with 30 fractions
within 6 weeks up to total irradiation doses of 20 to 120
Gy (9 dose groups, 6–8 animals per dose group). As in
the first experiment, carrier or BIBW 2992 were applied
4 hours before each irradiation fraction and continued
over the irradiation-free weekends, but not after the end
of irradiation.
Tumour volumes for both experiments at start of treat-
ments were approximately 100 mm3 (median volume
112 mm3, 10-90% = 100-160 mm3).92 up to the final size of the tumour. B) Fractionated irradiation
diation time. C) Fractionated irradiation (30f/6 weeks/total doses
irradiation time.
Figure 2 Effect on tumour growth time. Time to reach 2-fold or 5-fold the starting volume for A7, A431, FaDu, UT-SCC-14 and UT-SCC-15
xenografts receiving either carrier (○) or BIBW 2992 (◊) or the combined treatment of 15f/15d + carrier (closed circle symbol) or 15f/15d + BIBW
2992 (closed diamond symbol). Symbols represent median and bars 95% confidence intervals. p-value in comparison to control groups *significant
difference (comparison between BIBW 2992 vs. carrier or combined IR + BIBW 2992 vs. IR + carrier).
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Animals were observed up to final tumour size (mean
diameter exceeded 15 mm), until day 150 after the end of
treatment or until death. For UT-SCC-15 tumours that
were evaluated for local tumour control, it has been shown
before that almost all recurrences occur within that follow-
up time after radiotherapy [17]. In the local control experi-
ment 96% of 46 recurrences after irradiation occurred be-
fore day 126, the last recurrence was seen at day 130.
Animals that appeared to suffer needed to be killed before
these endpoints were reached.
Determinations of tumour volume and tumour growth time
Tumour diameters were determined twice per week.
With the formula for the rotational ellipsoid V = π/6 * a
* b2, where a is the longest and b is the perpendicular
shorter tumour axis, tumour volumes were calculated.
For each treatment arm the median tumour volumes
and their standard errors were computed as a function
of time after start of treatment. Evaluations were
stopped when < 50% of the animals of each treatment
arm were alive. From individual growth curves the
median tumour growth time was calculated as the time
that a regrowing tumour needed to reach 2 and 5 fold
of the starting volume (GDV2, GDV5). Enhancement
ratios (ER) were computed as the quotient of a GDvalue of BIBW 2992 treated tumours and the GD value
in the carrier treated group.
Dose–response curves for local tumour control and TCD50
values
150 days after end of irradiation tumour control rates were
calculated for each dose group after correction for censored
animals according to the method given by Walker and Suit
[31]. When an increased volume for at least three consecu-
tive measurements was observed after passing a nadir, re-
currences were scored. Animals that died from tumour-
independent reasons and therefore could not be followed
up, were censored at the last day of measurement.When
death occurred before day 20 after end of treatment ani-
mals (without recurred tumour) were excluded from the
analysis. Animals with local failure before death were not
excluded from the analysis but counted as failure. Based on
the individual tumour control data a binary (cure/failure)
model was used to fit tumour control probability (TCP)
curves. The TCP was modeled using the logit model
TCP ¼ 1=½1 þ exp ð−f ðx; βÞ
where x = vector of covariates that define the treatment,
β = vector of parameters describing radiosensitivity of
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these. Parameters were estimated using maximum likeli-
hood as implemented in STATA 7.0 software (STATA
Corporation, College Station TX). Quoted confidence
limits are asymptotic estimates from the results of the
likelihood fits. Comparison of maximum likelihood fits was
performed using the likelihood ratio test. Tumour control
dose 50% (TCD50) at day 150 after end of irradiation and
associated dose–response curve were determined from:
f D; βð Þ ¼ β1 1−D=β2ð Þ where β1 is a constant and TCD50 ¼ β2:
Cell survival in vitro
Tumour cells of the different cell lines were grown in
Dulbeccos modified Eagle’s medium with glutamine, 10%
fetal calf serum, 1 mM pyruvate, 1% non-essential amino
acids, 20 mM HEPES and 1% Penicillin-Streptomycin at
37°C (5% CO2, 95% humidity) in 25 cm
2 tissue culture
flasks. For the A7 tumour model MEM-EARLE with 10%
fetal calf serum and 1 mM pyruvate was used as medium.
After 24 hours cells were incubated with BIBW 2992 or
for control with dimethylsulfoxid (DMSO). Three days
later, cells were irradiated with doses of 2, 4, 6 or 8 Gy.
Directly after irradiation (200 kV x-rays, 0.5 mm Cu, ~1
Gy/min) cells were trypsinised and counted. Appropri-
ately diluted single cell suspensions were incubated in
petri dishes for 14 or 10 days (A431), fixed and stained
with crystal violet.Colonies with ≥ 50 cells were scored
as survivors. Mean values of the surviving fraction and
their standard deviations (SD) were determined for
each treatment group and dose level. Cell survival
curves were fitted according to the LQ-model. Plating
efficiencies (PE) and surviving fractions (SF) were cal-
culated using the following formulas:
PE ¼ colonies=plated cellsð Þ  100%;
SF ¼ PE of each dose= PE 0 Gyð Þ  100%:
Results
Figure 2 shows the relative tumour volume as a function
of time after start of treatment for all 5 tumour models.
For each of the 4 different treatment arms growth time
is presented as the time for tumours to reach the 2-fold
(GDV2) and 5-fold (GDV5) of the starting volume. The
application of BIBW 2992 alone leads to a significant
prolongation of tumour growth time in all tumour
models with considerable intertumoural heterogeneity.
While for the A7 tumour model only a slight prolongation
of tumour growth can be seen, a distinct effect was
observed for the FaDu-, A431-, UT-SCC-14 and UT-SCC-
15 tumour models. A complete regression of all tumours
during continuous application of BIBW 2992 alone without
recurrence seen during treatment time (mean 73 days) was
determined in the UT-SCC-14, A431 and UT-SCC-15tumours. During fractionated irradiation (15 fractions
within 15 days, total dose 30 Gy) a significant prolonga-
tion of tumour growth by BIBW 2992 could be observed
for the A7, A431 and UT-SCC-15 tumour models where
as this effect was not evident in FaDu and UT-SCC-14
tumours (Table 1). The larger growth inhibiting effect
of BIBW 2992 alone compared to the combination with
fractionated irradiation can be seen as a consequence of
the shorter administration within the combined treat-
ment schedule.
Figure 3 depicts the dose response curves for the local
tumour control experiment in UT-SCC-15 tumours after
fractionated irradiation (30 fractions within 6 weeks) with
or without simultaneous application of BIBW 2992. The
TCD50 is not significantly altered when BIBW 2992 is
added to fractionated irradiation. The TCD50 for irradiation
alone is 40.7 Gy [95% CI: 32;51] and for the simultaneous
BIBW 2992 administration 32.2 Gy [18;42] (p = 0.104).
Figure 4 illustrates the cell survival curves in vitro
for the different cell lines. For the tumour models
FaDu, A431, UT-SCC-14 and UT-SCC-15 no radiosen-
sitizing effect by incubation with BIBW 2992 could be
detected. Only in the A7 glioblastoma cells a slight and
for the dose group of 2 and 6 Gy significant radiose-
nitization could be seen (p-value for 2 Gy = 0.050;
p-value for 6 Gy =0.046).
Table 2 shows the heterogeneity of the cytotoxic effect
of BIBW 2992 on clonogenic tumour cells (plating
efficiency, PE) between the 5 cell lines. While there is no
effect of incubation with BIBW 2992 on the clonogeni-
city of A7-, FaDu- and A431 cells, a significant reduction
of clonogenic cell survival could be observed for the
UT-SCC-14, UT-SCC-15 cells.
Discussion
The present experiments are the first to test the effect of
combined fractionated irradiation and an EGFR/ErbB-
TK inhibitor on tumour growth time and local tumour
control. 4 different squamous cell carcinoma cell lines
with heterogeneous radiosensitivity and a radioresistant
glioma cell line were selected. We could show a hetero-
geneous effect on tumour growth time in these 5 differ-
ent tumour xenografts tested for the administration of
BIBW 2992 alone or in combination with fractionated
irradiation. These findings are in line with previous
experiments, where a prolongation of tumour growth
time was seen for the treatment of BIBW 2992 with or
without single dose irradiation in the FaDu tumour
model [16] or bladder tumour model [32]. Li et al. [29]
also showed an antiproliferative effect on A431 tumour
xenografts by a daily oral application of BIBW 2992
alone [29]. The major intertumoural heterogeneity of the
antiproliferative effect is in line with previous experience
on the selective EGFR-TK inhibitor erlotinib in 5
Figure 3 Observed local tumour control rates (symbols) and
calculated local tumour control probabilities for UT-SCC-15
tumours treated with 30 fractions in 6 weeks. Simultaneously to
fractionated irradiation animals received carrier (o, dotted line) or BIBW
2992 (•, solid line). Error bars represent 95% C.I. of the TCD50 values.
Table 1 Time to reach 2-fold or 5-fold of the starting volume for the five different tumour models and 4 different
treatment arms
Carrier BIBW 2992 15f/15d + carrier 15f/15d + BIBW 2992
A7 -Glioblastoma
GDV2(95% C.I.) 6 d (6; 7) 6.5 d (4; 8) 16 d (7; 48) 59.5 d (24; 65)
ER/p-value 1.08/1.00 3.72/0.01
GDV5(95% C.I.) 12 d (11; 13) 16 d (13; 21) 56 d (53; 64) 67 d (56; 72)
ER/p-value 1.33/0.01 1.20/0.02
FaDu–SCC from the head and neck
GDV2(95% C.I.) 4 d (3; 5) 51 d (35; 65) 45 d (41; 48) 49 d (40; 52)
ER/p-value 12.75/<0.0001 1.09/0.63
GDV5(95% C.I.) 11.5 d (10; 16) 90 d (55;112) 54 d (47; 64) 56 d (49; 63)
ER/p-value 7.83/<0.0001 1.04/0.87
UT-SCC-14 – SCC from the head and neck
GDV2(95% C.I.) 7.5 d (6; 9) n. a. 50 d (41; 103) 61 d (51; 85)
ER/p-value n. a. 1.22/0.30
GDV5(95% C.I.) 21 d (17; 26) n. a. 65 d (53; 122) 91.5 d (79; 111)
ER/p-value n. a. 1.41/0.15
A431–SCC from the cervix
GDV2(95% C.I.) 4.5 d (4; 7) n. a. 38 d (5; 43) 72 d (64; 84)
ER/p-value n. a. 1.89/<0.0001
GDV5(95% C.I.) 14.5 d (9; 15) n. a. 62.5 d (52; 66) 122 d (64; 141)
ER/p-value n. a. 1.95/0.0050
UT-SCC-15 –SCC from the head and neck
GDV2(95% C.I.) 5 d (5; 8) n. a. 34 d (15; 42) 56.5 d (48; 148)
ER/p-value n. a. 1.66/0.03
GDV5(95% C.I.) 16 d (14; 20) n. a. 50 d (43; 100) 109 d (61; 182)
ER/p-value n. a. 2.18/0.04
ER and p-values in comparison to control groups. n.a. – not applicable (tumours did not reach these endpoints).
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comparison between different experiments, one could
conclude that the dual inhibition of EGFR and ErbB-
receptor shows no larger effect on the prolongation of
tumour growth in the three models treated in both experi-
ments compared to the EGFR-TK inhibitor erlotinib. For
UT-SCC-14 and −15 an infinite prolongation with erloti-
nib or BIBW 2992 could be observed in both experiments.
For FaDu, the ER for application of erlotinib was 1.5 for
GDV5 and for BIBW 2992 an ER of 7.8 for the same end-
point was determined [8]. The latter appears at the first
glance as a difference and an advantage for the EGFR-TK
inhibitor, but this may well be artificially impacted by the
treatment within different experiments.
Local tumour control was evaluated in UT-SCC-15,
the cell line with the best response on clonogenic sur-
vival after incubation with BIBW 2992 alone in vitro and
with the largest effect of the combined treatment on
tumour growth in vivo. The A7 cell line showed also a
minimal but significant radiosensitizing effect in vitro.
However, because of the small amount of this effect andthe lower response of this cell line regarding the other
endpoints, this was not further followed up. Regarding
the effect on local tumour control in UT-SCC-15, there
was no benefit seen by the simultaneous ErbB family
inhibition with BIBW 2992 during fractionated irradiation
Figure 4 Clonogenic cell survival of A7, A431, FaDu, UT-SCC-14 and UT-SCC-15 cells irradiated with different total doses after three
days incubation with normal medium (DMSO; o) or BIBW 2992 (•), plating directly after irradiation. Symbols and error bars represent
means and standard deviations of three independent experiments (duplicates). The data were fitted according to the LQ model (dotted line = normal
medium, solid line = BIBW 2992).* significant difference (for dose groups in comparison to control group).
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tween fractionated irradiation alone or combined with
BIBW 2992. The local tumour control data are compar-
able to previous experiences where an inhibition of
tumour growth by EGFR-TK inhibitors did not translate
into an improvement on local tumour control in different
tumour models [1,8,28,33].
Animals receiving BIBW 2992 with or without radi-
ation tolerated the drug well (body weight measured
weekly as indicator of well being). Common side effects
were erythema of the mouth and diarrhea as described
before by Schütze et al. [16]. After an application period
of approximately 73 days within the first experiment
animals started to lose body weight and died or needed to
be sacrificed due to reduced general condition. Therefore
we reduced the BIBW 2992 dose for the local tumour
control experiment to 22.5 mg/kg b.w.. For early clinical
studies on systemic treatment alone (without radiother-
apy) the same side effects (erythema and diarrhea) have
been observed [34-36] and resemble experiences with
other TK-inhibitors like gefitinib or erlotinib [37,38].Table 2 Plating efficiency in vitro after incubation with either n
Tumor A7 FaDu
0 Gy DMSO (%) 5.76 19.49
0 Gy BIBW 2992 (%) 5.70 22.14
ER/p-Wert 1.01/0.9733 0.88/0.4274
Enhancement Ratio (ER) calculated as quotient of PEnormal medium and PEBIBW 2992 foIt can only be speculated which reasons underly the
missing translation of the positive effect on tumour
growth into improvement of local tumour control for
TK-inhibitors in comparison to antibodies like for
example cetuximab. One potential reason could still be
an alternative signal transduction. Hu et al. [39] re-
ported a cross talk of the EGFR with the insulin-like
growth factor receptor (IGF1R) [39]. Incubating tumour
cells with gefitinib or erlotinib led to an increased
heterodimerisation of IGF1R and EGFR resulting in a
pronounced IGF1R-activation and therefore amplified
activation of downstream mediators [1,40,41]. In these
in-vitro experiments, the induced resistance to EGFR-
TKI could be overcome by IGF1R-inhibitors [1,40,41].
Independent on the biological reasons, the differential
effect of BIBW 2992 on tumour proliferation versus
local tumour control is finally caused by a missing net
effect on cancer stem cells. This is based on the know-
ledge that all cancer stem cells need to be eliminated to
cure a tumour and that a single surviving cancer stem





r each cell line.
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CSC survival in situ [42]. It is interesting to note that
BIBW 2992 in vitro does inactivate clonogenic cells
in UT-SCC-15 and UT-SCC-14 independent from the
irradiation effect (Table 2). If this independent clono-
genic cell kill would translate into an inactivation of
cancer stem cells in vivo, one would have expected an
improvement of local tumour control by the combined
treatment. Reasons for the missing translation might be
that BIBW 2992 and irradiation preferentially target the
same tumour cell population, thus diluting the cytotoxic
effect of BIBW 2992 when combining these treatments.
Conclusion
The present experiments show a heterogeneous effect
of the ErbB family TK inhibitor BIBW 2992 on tumour
growth in 5 different tumour models for drug applica-
tion alone as well as in combination with a fractionated
radiotherapy. The major effect on tumour growth in
UT-SCC-15 tumours did not translate into an impro-
vement of local tumour control. Along with previous
experiments on combined fractionated irradiation and
EGFR-TK inhibition, it appears likely that TKI do not
affect survival of tumour cells that can cause recur-
rences but can lead to a good palliative effect by prolon-
ing tumour growth for a reasonable amount of time.
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